JP7773195B2 - がん治療のための治療用ペプチドに関する方法および組成物 - Google Patents

がん治療のための治療用ペプチドに関する方法および組成物

Info

Publication number
JP7773195B2
JP7773195B2 JP2021535554A JP2021535554A JP7773195B2 JP 7773195 B2 JP7773195 B2 JP 7773195B2 JP 2021535554 A JP2021535554 A JP 2021535554A JP 2021535554 A JP2021535554 A JP 2021535554A JP 7773195 B2 JP7773195 B2 JP 7773195B2
Authority
JP
Japan
Prior art keywords
cancer
cells
elane
peptide
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021535554A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022514354A5 (https=
JP2022514354A (ja
JPWO2020132465A5 (https=
Inventor
レブ ベッカー
チャン ツゥイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Chicago
Original Assignee
University of Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Chicago filed Critical University of Chicago
Publication of JP2022514354A publication Critical patent/JP2022514354A/ja
Publication of JP2022514354A5 publication Critical patent/JP2022514354A5/ja
Publication of JPWO2020132465A5 publication Critical patent/JPWO2020132465A5/ja
Priority to JP2025183107A priority Critical patent/JP2026021440A/ja
Application granted granted Critical
Publication of JP7773195B2 publication Critical patent/JP7773195B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/486—Elastase (3.4.21.36 or 3.4.21.37)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21037—Leukocyte elastase (3.4.21.37), i.e. neutrophil-elastase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2021535554A 2018-12-20 2019-12-20 がん治療のための治療用ペプチドに関する方法および組成物 Active JP7773195B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025183107A JP2026021440A (ja) 2018-12-20 2025-10-30 がん治療のための治療用ペプチドに関する方法および組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862782690P 2018-12-20 2018-12-20
US62/782,690 2018-12-20
PCT/US2019/067890 WO2020132465A1 (en) 2018-12-20 2019-12-20 Methods and compositions related to therapeutic peptides for cancer therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025183107A Division JP2026021440A (ja) 2018-12-20 2025-10-30 がん治療のための治療用ペプチドに関する方法および組成物

Publications (4)

Publication Number Publication Date
JP2022514354A JP2022514354A (ja) 2022-02-10
JP2022514354A5 JP2022514354A5 (https=) 2022-12-06
JPWO2020132465A5 JPWO2020132465A5 (https=) 2022-12-06
JP7773195B2 true JP7773195B2 (ja) 2025-11-19

Family

ID=71101609

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021535554A Active JP7773195B2 (ja) 2018-12-20 2019-12-20 がん治療のための治療用ペプチドに関する方法および組成物
JP2025183107A Pending JP2026021440A (ja) 2018-12-20 2025-10-30 がん治療のための治療用ペプチドに関する方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025183107A Pending JP2026021440A (ja) 2018-12-20 2025-10-30 がん治療のための治療用ペプチドに関する方法および組成物

Country Status (6)

Country Link
EP (1) EP3897669A4 (https=)
JP (2) JP7773195B2 (https=)
CN (2) CN113677351B (https=)
AU (1) AU2019403393B2 (https=)
CA (1) CA3123853A1 (https=)
WO (1) WO2020132465A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4199947A4 (en) 2020-08-18 2024-10-16 Onchilles Pharma, Inc. Modified porcine pancreatic elastase proteins
WO2022056488A1 (en) * 2020-09-14 2022-03-17 Genprex, Inc. Nonviral vectors for increasing fas expression in cancer cells and methods of use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120183552A1 (en) 2005-03-25 2012-07-19 Celera Corporation Kidney disease targets and uses thereof
JP2015536318A (ja) 2012-10-17 2015-12-21 バスキュラー バイオジェニックス リミテッド アデノウイルスを用いた治療方法
WO2018073394A1 (en) 2016-10-19 2018-04-26 Cellectis Cell death inducing chimeric antigen receptors
JP2018512154A (ja) 2015-04-13 2018-05-17 ユーシーエル ビジネス ピーエルシー キメラタンパク質

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP1178817A2 (en) * 1999-05-14 2002-02-13 Arbor Vita Corporation Molecular interactions in haematopoietic cells
WO2008067305A2 (en) * 2006-11-28 2008-06-05 Giic Research Development Corporation Polypeptides comprising intracytoplasmic death domain and nkg2d ligand domain
ES2523992T3 (es) * 2006-12-28 2014-12-03 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts La neutralización de la actividad de CD95 bloquea la invasión de células de glioblastoma in vivo
JP6153526B2 (ja) * 2011-09-06 2017-06-28 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ ポリペプチドワクチン
GB201121070D0 (en) 2011-12-07 2012-01-18 Isis Innovation composition for delivery of biotherapeutics
WO2014118643A2 (en) * 2013-02-04 2014-08-07 Vascular Biogenics Ltd. Methods of inducing responsiveness to anti-angiogenic agent
EP4292606B1 (en) * 2017-06-15 2025-11-12 The University of Chicago Compositions for treating cancer
WO2019051001A1 (en) * 2017-09-06 2019-03-14 California Institute Of Technology SIGNALING AND BIFUNCTIONAL RECEPTORS HAVING ANTIGENS (SABR)

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120183552A1 (en) 2005-03-25 2012-07-19 Celera Corporation Kidney disease targets and uses thereof
JP2015536318A (ja) 2012-10-17 2015-12-21 バスキュラー バイオジェニックス リミテッド アデノウイルスを用いた治療方法
JP2018512154A (ja) 2015-04-13 2018-05-17 ユーシーエル ビジネス ピーエルシー キメラタンパク質
WO2018073394A1 (en) 2016-10-19 2018-04-26 Cellectis Cell death inducing chimeric antigen receptors

Also Published As

Publication number Publication date
AU2019403393A1 (en) 2021-08-05
CA3123853A1 (en) 2020-06-25
EP3897669A4 (en) 2022-08-24
JP2022514354A (ja) 2022-02-10
JP2026021440A (ja) 2026-02-10
CN113677351B (zh) 2024-09-27
EP3897669A1 (en) 2021-10-27
CN113677351A (zh) 2021-11-19
AU2019403393B2 (en) 2026-04-16
WO2020132465A1 (en) 2020-06-25
CN119015448A (zh) 2024-11-26
US20220000977A1 (en) 2022-01-06

Similar Documents

Publication Publication Date Title
JP7529754B2 (ja) がんを処置するための方法および組成物
Hou et al. Navigating CAR-T cells through the solid-tumour microenvironment
Shin et al. Curvature-sensing peptide inhibits tumour-derived exosomes for enhanced cancer immunotherapy
JP2026021440A (ja) がん治療のための治療用ペプチドに関する方法および組成物
CN104284680A (zh) 使用对受体的亲和力增加的突变型light分子用于癌症治疗的方法和组合物
US20170198054A1 (en) Methods for treating cancer with anti bip or anti mica antibodies
US12611443B2 (en) Methods and compositions related to therapeutic peptides for cancer therapy
HK40119649A (zh) 与用於癌症疗法的治疗肽相关的方法和组合物
WO2013009165A1 (en) A peptide capable of binding with a human leukocyte antigen (hla) molecule, a cancer vaccine derived from said peptide and use of said cancer vaccine
HK40102823B (en) Compositions for treating cancer
HK40102823A (en) Compositions for treating cancer
Orsolic Possible molecular targets of bee venom in the treatment of cancer: application and perspectives
HK40029045A (en) Compositions for treating cancer
HK40029045B (en) Compositions for treating cancer
US20250066420A1 (en) Pd-l1 inhibitory peptide for cancer immunotherapy
CA3071217A1 (en) Hsp70 based combination therapy
HK40099663A (zh) 用於治疗癌症的治疗性rna

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221128

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221128

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230622

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231002

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240329

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240628

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250630

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251002

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251030

R150 Certificate of patent or registration of utility model

Ref document number: 7773195

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150